___

• 1. Sumer, B. and Gao, J. (2008). Theranostic nanomedicine for cancer. Nanomedicine, 3(2), 137– 140.
• 2. Kurdziel, K., Ravizzini, G., Croft, B.Y., Tatum, J.L., Choyke, P.L., Kobayashi, H. (2008). The evolving role of nuclear molecular imaging in cancer. Expert Opinion on Medical Diagnostics, 2(7), 829–842.
• 3. Bozkurt, M.F. and Özcan, Z. (2018). The evolving role of nuclear medicine and molecular imaging: theranostics and personalized therapeutic applications. Molecular Imaging and Radionuclide Therapy, 27, 1–2.
• 4. Aulić, S., Bolognesi, M.L., Legname, G. (2013). Small-molecule theranostic probes: A promising future in neurodegenerative diseases. International Journal of Cell Biology, 2013, 150952.
• 5. Kim, T.H., Lee, S. and Chen, X. (2013). Nanotheranostics for personalized medicine. Expert Review of Molecular Diagnostics, 13(3), 257–269.
• 6. Swierczewska, M., Liu, G., Lee, S., Chen, X. (2012). High-sensitivity nanosensors for biomarker detection. Chemical Society Reviews, 41(7), 2641–2655.
• 7. Chikkaveeraiah, B.V., Bhirde, A.A., Morgan, N.Y., Eden, H.S., Chen, X. (2012). Electrochemical immunosensors for detection of cancer protein biomarkers. ACS Nano, 6(8), 6546–6561.
• 8. Farokhzad, O.C. and Langer, R. (2006). Nanomedicine: Developing smarter therapeutic and diagnostic modalities. Advanced Drug Delivery Reviews, 58(14), 1456–1459.
• 9. Funkhouser, J. (2002). Reinventing pharma: The theranostic revolution. Current Drug Discovery, 2, 17–19.
• 10. Durak, H. (2015). Onkolojide kişiselleştirilmiş tedavi ve teranostik yaklaşımlar. Nükleer Tıp Seminerleri, (2), 80–4.
• 11. Kalash, R.S., Lakshmanan, V.K., Cho, C.-S., Park, I.-K. (2016). Theranostics. In: M. Ebara (Ed.), Biomaterials Nanoarchitectonics, (p. 197–215). 1st Edition. Elsevier Inc.: William Andrew.
• 12. Cancer Web site. (2018). Retrieved Jan 17, 2020, from https://www.who.int/news-room/fact sheets/detail/cancer.
• 13. Nayak, K.A. and Pal, D. (2010). Nanotechnology for targeted delivery in cancer therapeutics. Seemanta Institute of Pharmaceutical Sciences, 1(1), 1–7.
• 14. Wang, L.V. (2004). Ultrasound-mediated biophotonic imaging: A review of acousto-optical tomography and photo-acoustic tomography. Disease Markers, 19, 123–138.
• 15. Singh, K. (2005). Nanotechnology in cancer detection and treatment. Technology in Cancer Research and Treatment, 4, 583–584.
• 16. National Cancer Institute Web site. (2004). "Cancer Nanotechnology". Retrieved Jan 25, 2020, from https://nano.cancer.gov/.
• 17. Oylar, Ö. and Tekin, İ. (2011). Nanotechnology in cancer diagnosis and treatment. Uludağ Üniversitesi Mühendislik-Mimarlık Fakültesi Dergisi, 16(1), 147–154.
• 18. Erdoğan, A. and Özkan, A. (2013). Kanser tedavisinde ve tümör görüntülemesinde nanoteknolojik uygulamalar. Arşiv Kaynak Tarama Dergisi, 22(3), 426–440.
• 19. Şengel-Türk, C. and Hasçiçek, C. (2009). Polimerik nanopartiküller ilaç taşıyıcı sistemlerde yüzey modifikasyonu. Ankara Universitesi Eczacilik Fakultesi Dergisi, 38, 137–154.
• 20. Mura, S. and Couvreur, P. (2012). Nanotheranostics for personalized medicine. Advanced Drug Delivery Reviews, 64(13), 1394-1416.
• 21. Yang, J., Lee, C.H., Ko, H.J., Suh, J.S., Yoon, H.G., Lee, K., Huh, Y.M., Haam, S. (2007). Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angewandte Chemie - International Edition, 46(46), 8836– 8839.
• 22. Liu, Y., Ibricevic, A., Cohen, J.A., Cohen, J.L., Gunsten, S.P., Fréchet, J.M., Walter, M.J., Welch, M.J., Brody, S.L. (2009). Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics. Molecular Pharmaceutics, 6(6), 1891–1902.
• 23. Lim, E.K., Huh, Y.M., Yang, J., Lee, K., Suh, J.S., Haam, S. (2011). PH-triggered drug releasing magnetic nanoparticles for cancer therapy guided by molecular imaging by MRI. Advanced Materials, 23(21), 2436–2442.
• 24. Hyung, W., Ko, H., Park, J., Lim, E., Park, S.B., Park, Y.J., Yoon, H.G., Suh, J.S., Haam, S., Huh, Y.M. (2008). Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment. Biotechnology and Bioengineering, 99(2), 442–454.
• 25. Gatenby, R.A. and Gawlinski, E.T. (1996). A reaction-diffusion model of cancer invasion. Cancer Research, 56(24), 5745–5753.
• 26. Wickham, T.J. (2003). Ligand-directed targeting of genes to the site of disease. Nature Medicine, 9(1), 135–139.
• 27. Saltzman, W.M. (2001). Drug Delivery, Oxford University Press, New York, p.384.
• 28. Wang, Z., Niu, G., Chen, X. (2014). Polymeric materials for theranostic applications. Pharmaceutical Research, 31(6), 1358–1376.
• 29. Sezgin Bayındır, Z. and Yüksel, N. (2007). Pegilasyon: PEG konjugatlarının hazırlanması ve uygulamaları. Ankara Universitesi Eczacilik Fakultesi Dergisi, 36(4), 249–266.
• 30. Tüylek, Z. (2017). İlaç taşıyıcı sistemler ve nanoteknolojik etkileşim. Bozok Medical Journal, 7(3), 89–98.
• 31. Jackson, E.F., Esparza-Coss, E., Wen, X., Ng, C.S., Daniel, S.L., Price, R.E., Rivera, B., Charnsangavej, C., Gelovani, J.G., Li, C. (2007). Magnetic resonance imaging of therapy induced necrosis using gadolinium-chelated polyglutamic acids. International Journal of Radiation Oncology Biology Physics, 68(3), 830–838.
• 32. Vaidya, A., Sun, Y., Ke, T., Jeong, E.K., Lu, Z.R. (2006). Contrast enhanced MRI-guided photodynamic therapy for site-specific cancer treatment. Magnetic Resonance in Medicine, 25(9), 2002–2011.
• 33. Tan, M. and Lu, Z.-R. (2011). Integrin targeted MR imaging. Theranostics, 1, 83–101.
• 34. Haag, R. (2004). Supramolecular drug-delivery systems based on polymeric core-shell architectures. Angewandte Chemie - International Edition, 43(3), 278–282.
• 35. Mitra, A., Nan, A., Line, B.R., Ghandehari, H. (2006). Nanocarriers for nuclear imaging and radiotherapy of cancer. Current Pharmaceutical Design, 12(36), 4729–4749.
• 36. Portney, N.G. and Ozkan, M. (2006). Nano-oncology: Drug delivery, imaging, and sensing. Analytical and Bioanalytical Chemistry, 384(3), 620–630.
• 37. Kaida, S., Cabral, H., Kumagai, M., Kishimura, A., Terada, Y., Sekino, M., Aoki, I., Nishiyama, N., Tani, T., Kataoka, K. (2010). Visible drug delivery by supramolecular nanocarriers directing to single-platformed diagnosis and therapy of pancreatic tumor model. Cancer Research, 70(18), 7031–7041.
• 38. Nasongkla, N., Bey, E., Ren, J., Ai, H., Khemtong, C., Guthi, J.S., Chin, S.F., Sherry, A.D., Boothman, D.A., Gao, J. (2006). Multifunctional polymeric micelles as cancer-targeted, MRI ultrasensitive drug delivery systems. Nano Letters, 6(11), 2427–2430.
• 39. Muthu, M.S., Leong, D.T., Mei, L., Feng, S.S. (2014). Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics, 4(6), 660–677.
• 40. Vijayakumar, M.R., Muthu, M.S., Singh, S. (2013). Copolymers of poly(lactic acid) and d-α tocopheryl polyethylene glycol 1000 succinate-based nanomedicines: Versatile multifunctional platforms for cancer diagnosis and therapy. Expert Opinion on Drug Delivery, 10(4), 529–543.
• 41. Liu, Y., Feng, L., Liu, T., Zhang, L., Yao, Y., Yu, D., Wang, L., Zhang, N. (2014). Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer. Nanoscale, 6(6), 3231–3242.
• 42. Pan, G.-Y., Jia, H.-R., Zhu, Y.-X., Sun, W., Cheng, X.-T., Wu F.-G. (2018). Correction to cyanine-containing polymeric nanoparticles with imaging/therapy-switchable capability for mitochondria-targeted cancer theranostics. ACS Applied Nano Materials, 1(6), 2885–2897.
• 43. Akhter, S., Ahmad, M.Z., Ahmad, F.J., Storm, G., Kok, R.J. (2012). Gold nanoparticles in theranostic oncology: Current state-of-the-art. Expert Opinion on Drug Delivery, 9(10), 1225– 1243.
• 44. Xiao, Y., Hong, H., Matson, V.Z., Javadi, A., Xu, W., Yang, Y., Zhang, Y., Engle, J.W., Nickles, R.J., Cai, W., Steeber, D.A., Gong, S. (2012). Gold nanorods conjugated with doxorubicin and cRGD for combined anti-cancer drug delivery and PET imaging. Theranostics, 2(8), 757–768.
• 45. Sayıner, Ö. and Çomoğlu, T. (2016). Nanotaşıyıcı sistemlerde hedeflendirme. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, 40(3), 62–79.,
• 46. Saad, M., Garbuzenko, O.B., Ber, E., Chandna, P., Khandare, J.J., Pozharov, V.P., Minko, T. (2008). Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging?. Journal of Controlled Release, 130(2), 107–114.
• 47. Taratula, O., Schumann, C., Naleway, M.A., Pang, A.J., Chon, K.J., Taratula, O. (2013). A multifunctional theranostic platform based on phthalocyanine-loaded dendrimer for image guided drug delivery and photodynamic therapy. Molecular Pharmaceutics, 10(10), 3946– 3958.
• 48. Sapra, P., Tyagi, P., Allen, T. (2005). Ligand-targeted liposomes for cancer treatment. Current Drug Delivery, 2(4), 369–381.
• 49. Zhao, Y.Z., Dai, D.D., Lu, C.T., Chen, L.J., Lin, M., Shen, X.T., Li, X.K., Zhang, M., Jiang, X., Jin, R.R., Li, X., Lv, H.F., Cai, L., Huang, P.T. (2013). Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer. Cancer Letters, 330(1), 74–83.
• 50. Saesoo, S., Sathornsumetee, S., Anekwiang, P., Treetidnipa, C., Thuwajit, P., Bunthot, S., Maneeprakorn, W., Maurizi, L., Hofmann, H., Rungsardthong, R.U., Saengkrit, N. (2018). Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma. Colloids and Surfaces B: Biointerfaces, 161, 497–507.
• 51. Wen, C.J., Zhang, L.W., Al-Suwayeh, S.A., Yen, T.C., Fang, J.Y. (2012). Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. International Journal of Nanomedicine, 7, 1599–1611.
• 52. Al-Jamal, W.T. Al-Jamal, K.T, Tian, B., Lacerda, L., Bomans, P.H., Frederik, P.M., Kostarelos, K. (2008). Lipid - Quantum dot bilayer vesicles enhance tumor cell uptake and retention in vitro and in vivo. ACS Nano, 2(3), 408–418.
• 53. Al-Jamal, W.T. and Kostarelos, K. (2011). Liposomes: From a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Accounts of Chemical Research, 44(10), 1094–1104.
• 54. Yong, K.T., Roy, I., Swihart, M.T., Prasad, P.N. (2009). Multifunctional nanoparticles as biocompatible targeted probes for human cancer diagnosis and therapy. Journal of Materials Chemistry, 19, 4655–4672.
• 55. Gao, X., Yang, L., Petros, J.A., Marshall, F.F., Simons, J.W., Nie, S. (2005). In vivo molecular and cellular imaging with quantum dots. Current Opinion in Biotechnology, 16(1), 63–72.
• 56. Xu, G., Mahajan, S., Roy, I., Yong, K.T. (2013). Theranostic quantum dots for crossing blood brain barrier in vitro and providing therapy of HIV-associated encephalopathy. Frontiers in Pharmacology, 4, 140.
• 57. Huang, H.-K., Yan, J., Liu, P., Zhao, B.-Y., Cao, Y., Zhang, X.-F. (2017). A novel cancer nanotheranostics system based on quantum dots encapsulated by a polymer-prodrug with controlled release behaviour. Australian Journal of Chemistry, 70(12), 1302–1311.
• 58. Bagalkot, V., Zhang, L., Levy-Nissenbaum, E., Jon, S., Kantoff, P.W., Langer, R., Farokhzad, O.C. (2007). Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on Bi-fluorescence resonance energy transfer. Nano Letters, 7(10), 3065–3070.
• 59. Silindir, M., Erdoğan, S., Özer, A.Y., Maia, S. (2012). Liposomes and their applications in molecular imaging. Journal of Drug Targeting, 20(5), 401–415.
• 60. Cole, J.T. and Holland, N.B. (2015). Multifunctional nanoparticles for use in theranostic applications. Drug Delivery and Translational Research, 5(3), 295–309.
• 61. Pysz, M.A., Gambhir, S.S., Willmann, J.K. (2010). Molecular imaging: current status and emerging strategies. Clinical Radiology, 65(7), 500–516.
• 62. Kao, H., Lin, Y.Y., Chen, C.C., Chi, K.H., Tien, D.C., Hsia, C.C., Lin, M.H., Wang, H.E. (2013). Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model. Bioorganic & Medicinal Chemistry Letters, 23(11), 3180–3185.
• 63. Gambhir, S.S. (2002). Molecular imaging of cancer with positron emission tomography. Nature Reviews Cancer, 2(9), 683–693.
• 64. Chen, F., Hong, H., Zhang, Y., Valdovinos, H.F., Shi, S., Kwon, G.S., Theuer, C.P., Barnhart, T.E., Cai, W. (2013). In vivo tumor targeting and ımage-guided drug delivery with antibody conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano, 7(10), 9027–9039.
• 65. Wang, C., Ravi, S., Garapati, U.S., Das, M., Howell, M., MallelaMallela, J., Alwarapan, S., Mohapatra, S.S., Mohapatra, S. (2013). Multifunctional chitosan magnetic-graphene (CMG) nanoparticles: A theranostic platform for tumor-targeted codelivery of drugs, genes and MRI contrast agents. Journal of Materials Chemistry B, 1(35), 4396–4405.
• 66. Panchapakesan, B., Book-Newell, B., Sethu, P., Rao, M., Irudayaraj, J. (2011). Gold nanoprobes for theranostics. Nanomedicine, 6(10), 1787–1811.
• 67. Lee, S., Xie, J., Chen, X. (2010). Activatable molecular probes for cancer imaging. Current Topics in Medicinal Chemistry, 10(11), 1135–1144.
• 68. Lee, S., Xie, J., Chen, X. (2010). Peptide-based probes for targeted molecular imaging. Biochemistry, 49(7), 1364–1376.
• 69. Tyagi, S. and Kramer, F.R. (1996). Molecular beacons: Probes that fluoresce upon hybridization. Nature Biotechnology, 14(3), 303–308.
• 70. Gültekin, N., Karaoǧlu, K., Küçükates, E. (2008). Hücrede apoptoz ve saǧkalım mekanizmalarinin keşfedilmesi ve yeni potansiyel tedavi stratejileri. Turk Kardiyoloji Dernegi Arsivi, 36(2), 120–130.
• 71. Kim, K. Lee, M., Park, H., Kim, J.-H., Kim, S., Chung, H., Choi, K., Kim, I.-S., Seong, B.L., Kwon, I.C. (2006). Cell-permeable and biocompatible polymeric nanoparticles for apoptosis imaging. Journal of the American Chemical Society, 128(11), 3490–3491.
• 72. Lee, S., Choi, K.Y., Chung, H., Ryu, J.H., Lee, A., Koo, H., Youn, I.C., Park, J.H., Kim, I.S., Kim, S.Y., Chen, X., Jeong, S.Y., Kwon, I.C., Kim, K., Choi, K. (2011). Real time, high resolution video imaging of apoptosis in single cells with a polymeric nanoprobe. Bioconjugate Chemistry, 22(2), 125–131.
• 73. Huang, X., Swierczewska, M., Choi, K.Y., Zhu, L., Bhirde, A., Park, J., Kim, K., Xie, J., Niu, G., Lee, K.C., Lee, S., Chen, X. (2012). Multiplex imaging of an intracellular proteolytic cascade by using a broad-spectrum nanoquencher. Angewandte Chemie - International Edition, 51(7), 1625–1630.
• 74. Chen, Y. Xianyu, Y., Wu, J., Yin, B., Jiang, X. (2016). Click chemistry-mediated nanosensors for biochemical assays. Theranostics, 6(7), 969–985.
• 75. Brennan, J.L., Hatzakis, N.S., Tshikhudo, T.R., Dirvianskyte, N., Razumas, V., Patkar, S., Vind, J., Svendsen, A., Nolte, R.J., Rowan, A.E., Brust, M. (2006). Bionanoconjugation via click chemistry: The creation of functional hybrids of lipases and gold nanoparticles. Bioconjugate Chemistry, 17(6), 1373–1375.
• 76. Cutler, J.I., Zheng, D., Xu, X., Giljohann, D.A., Mirkin, C.A. (2010). Polyvalent oligonucleotide iron oxide nanoparticle “click” conjugates. Nano Letters, 10(4), 1477–1480.
• 77. Chen, L., Li, H., He, H., Wu, H., Jin, Y. (2015). Smart plasmonic glucose nanosensors as generic theranostic agents for targeting-free cancer cell screening and killing. Analytical Chemistry, 87(13), 6868–6874.
• 78. Xia, Z., Xing, Y., So, M.K., Koh, A.L., Sinclair, R., Rao, J. (2008). Multiplex detection of protease activity with quantum dot nanosensors prepared by intein-mediated specific bioconjugation. Analytical Chemistry, 80(22), 8649–8655.
• 79. Wang, Q., Wang, C., Wang, X., Zhang, Y., Wu, Y., Dong, C., Shuang, S. (2019). Construction of CPs@MnO2-AgNPs as a multifunctional nanosensor for glutathione sensing and cancer theranostics. Nanoscale, 11, 18845–18853.
• 80. Perez, J.M., Josephson, L., Weissleder, R. (2004). Use of magnetic nanoparticles as nanosensors to probe for molecular interactions. ChemBioChem, 5(3), 261–264.
• 81. Vogenberg, F.R., Barash, C.I., Pursel, M. (2010). Personalized medicine - Part 1: Evolution and development into theranostics. Pharmacy and Therapeutics, 35(10), 560–576.
• 82. Bamrungsap, S., Zhao, Z., Chen, T., Wang, L., Li, C., Fu, T., Tan, W. (2012). Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine London England, 7(8), 1253–1271.
• 83. Sinha, R., Kim, G.J., Nie, S., Shin, D.M. (2006). Nanotechnology in cancer therapeutics: Bioconjugated nanoparticles for drug delivery. Molecular Cancer Therapeutics, 5(8), 1909– 1917.
• 84. Farokhzad, O.C., Langer, R. (2009). Impact of nanotechnology on drug delivery. ACS Nano, 3(1), 16–20.